XPO1 and acute myeloid leukemia: The XPO1 inhibitor selinexor also upregulates the purinergic receptor P2Ry2 in AML cells and thereby activates PI3K-AKT signaling; inhibition of this pathway potentiates the anti-leukemic effects of selinexor in experimental models [80].